Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (231-240 of 390) with videos related to

Pageof 39
Sort By:
Annals of Clinical and Translational Neurology|April 25, 2015
Comparative efficacy of switching to natalizumab in active multiple sclerosisTimothy Spelman, Tomas Kalincik, Annie Zhang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 1, 2026
Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansionDaniel Guilfoyle, Kayla Ward, Samuel Klistorner, et al.
Journal of the Neurological Sciences|June 19, 2026
Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remissionMeltem Karadeniz, Robb Wesselingh, Padmakrishnan C Jayakrishnan, et al.
Life Science Alliance|June 11, 2020
Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cellsMelissa M Gresle, Margaret A Jordan, Jim Stankovich, et al.
Neurology|March 11, 2014
Fingolimod after natalizumab and the risk of short-term relapseVilija G Jokubaitis, Vivien Li, Tomas Kalincik, et al.
American Journal of Human Genetics|April 2, 2002
Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosisJustin P Rubio, Melanie Bahlo, Helmut Butzkueven, et al.
Therapeutic Advances in Neurological Disorders|September 29, 2023
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across EuropeRichard Nicholas, Jeff Rodgers, James Witts, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2018
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosisMyintzu Min, Tim Spelman, Alessandra Lugaresi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 14, 2024
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapseBenjamin P Trewin, Russell C Dale, Jessica Qiu, et al.
Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Pageof 39

Showing results (231-240 of 390) with videos related to

Sort By:
Pageof 39
Annals of Clinical and Translational Neurology|April 25, 2015
Comparative efficacy of switching to natalizumab in active multiple sclerosisTimothy Spelman, Tomas Kalincik, Annie Zhang, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 1, 2026
Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansionDaniel Guilfoyle, Kayla Ward, Samuel Klistorner, et al.
Journal of the Neurological Sciences|June 19, 2026
Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remissionMeltem Karadeniz, Robb Wesselingh, Padmakrishnan C Jayakrishnan, et al.
Life Science Alliance|June 11, 2020
Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cellsMelissa M Gresle, Margaret A Jordan, Jim Stankovich, et al.
Neurology|March 11, 2014
Fingolimod after natalizumab and the risk of short-term relapseVilija G Jokubaitis, Vivien Li, Tomas Kalincik, et al.
American Journal of Human Genetics|April 2, 2002
Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosisJustin P Rubio, Melanie Bahlo, Helmut Butzkueven, et al.
Therapeutic Advances in Neurological Disorders|September 29, 2023
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across EuropeRichard Nicholas, Jeff Rodgers, James Witts, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2018
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosisMyintzu Min, Tim Spelman, Alessandra Lugaresi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 14, 2024
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapseBenjamin P Trewin, Russell C Dale, Jessica Qiu, et al.
Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Pageof 39